Despite compelling evidence that genetic factors contribute to bipolar disorder (BP), attempts to identify susceptibility genes have met with limited success. This may be due to the genetic heterogeneity of the disorder. We sought to identify susceptibility loci for BP in a genome-wide linkage scan with and without clinical covariates that might reflect the underlying heterogeneity of the disorder. We genotyped 428 subjects in 98 BP families at the Center for Inherited Disease Research with 402 microsatellite markers. We first carried out a nonparametric linkage analysis with MERLIN, and then reanalyzed the data with LODPAL to incorporate clinical covariates for age at onset (AAO), psychosis and comorbid anxiety. We sought to further examine the top findings in the covariate analysis in an independent sample of 64 previously collected BP families. In the non-parametric linkage analysis, three loci were nominally significant under a narrow diagnostic model and seven other loci were nominally significant under a broader model. The top findings were on chromosomes 2q24 and 3q28. The covariate analyses yielded additional evidence for linkage on 3q28 with AAO in the primary and independent samples. Although none of the linked loci were genome-wide significant, their congruence with prior results and, for the covariate analyses, their identification in two separate samples increases the likelihood that they are true positives and deserve further investigation. These findings further demonstrate the value of considering clinical features that may reflect the underlying heterogeneity of disease in order to facilitate gene mapping.
Introduction
Despite compelling evidence from family, twin and adoption studies that genetic factors contribute significantly to bipolar disorder (BP), attempts to identify susceptibility of genes to the disorder have met with limited success. Linkage studies have identified many loci across the genome that may be linked to BP, including several that have achieved genome-wide significance on chromosomes 2p13-16, 4p16, 4q32, 6q21-25, 8q24, 12q22-24 and 15q14. Similarly, numerous studies have reported modest associations with a wide array of different candidate genes such as, for example, MAOA, COMT, 5-HTT, BDNF and DAOA. 1 The problem with the linkage and association findings reported thus far is that they have not been consistently replicated, making it difficult to draw definitive conclusions about their true contribution to BP susceptibility. One reason for the difficulty is that the etiology of BP is apparently very complex. There might be a number of genes that contribute to BP susceptibility, and these genes might act independently and/or interactively with each other in multiple different pathways such that each individual gene exerts only a small marginal effect on disease. A potential strategy for overcoming the challenges posed by this complexity is to study more etiologically homogeneous groups of patients. Previous studies have shown that certain clinical features aggregate in subsets of families with BP and, therefore, may be observable manifestations of the underlying genetic heterogeneity. 2 As a result, it may be possible to use these clinical features to facilitate gene hunting efforts.
Here, we report the results of a genome-wide linkage scan using 98 new BP pedigrees ascertained for a collaborative study. We first conducted a multi-point non-parametric linkage analysis and then followed this up with a linkage analysis using clinical covariates to address potential genetic heterogeneity and further help locate linked regions of interest. We examined clinical covariates found in our previous research to aggregate in BP families, including age at onset (AAO), psychosis and comorbid anxiety disorders. We sought to replicate the top findings in these covariate analyses using a sample of 64 pedigrees that were ascertained by our group and reported previously. 3 
Materials and methods

Primary Sample
The 98 new BP pedigrees in this study were ascertained based on a treated bipolar I (BPI) proband plus at least two first-degree relatives with a major mood disorder, defined as schizoaffective disorder, manic type (SAM), BPI, bipolar II disorder with recurrent major depression (BPII) or recurrent major depression (MDDR). Recruitment for this study, now referred to as CHIP, was conducted at University of Chicago, Johns Hopkins, and the NIMH Intramural Program. Clinicians conducted diagnostic interviews using the Schedule for Affective Disorders and Schizophrenia -Lifetime Version (SADS-L) 4 or the Diagnostic Interview for Genetic Studies (DIGS). 5 Family history information was collected and medical records also obtained when available. Diagnoses were made according to Research Diagnostic Criteria (RDC) 6 using best estimate procedures in which two non-interviewing psychiatrists assigned separate diagnoses and a third psychiatrist arbitrated a final decision if they disagreed. All subjects provided written informed consent before enrolling in the study.
The pedigrees were genotyped at the Center for Inherited Disease Research (CIDR) with 402 microsatellite markers at an average distance of 9 cM across the genome with no gaps > 20 cM in length (http:// www.cidr.jhmi.edu/). Genetic distances were based on Marshfield's genetic map. The overall missing data rate was 4.3%, and the estimated error rate based on comparison of duplicates was 0.04% per genotype. The data were examined with PREST to identify problematic pedigree relationship assignments. Subjects whose relationship could not be reconciled with their genotype data were deleted. The data were then checked for Mendelian inconsistencies using both PEDCHECK and UNKNOWN. Problematic genotypes were deleted when they could not be resolved. Finally, the data were analyzed using the error routine of MERLIN and genotypes suggesting unlikely double recombinations were removed.
The final sample after all corrections included 428 genotyped subjects in 98 pedigrees. Of these, 282 were diagnosed with a major mood disorder, including four with SAM, 121 with BPI, 80 with BPII and 77 with MDDR. Under the narrow affection status model defined below, there were 71 independent sib pairs, 86 all possible sib pairs and 120 relative pairs. Under the broad affection status model, there were 123 independent sib pairs, 162 all possible sib pairs and 239 relative pairs (see Table 1 ).
Independent sample
The independent sample consisted of 64 pedigrees that were part of a genome-wide scan we carried out and reported previously. 3 These pedigrees were ascertained and assessed using procedures similar to those described above. They were genotyped by CIDR in two different stages. The first set of 43 families was genotyped, as part of the previous genome-wide linkage scan, with a panel of 355 markers spaced an average of 9.5 cM across the genome. The second set of 21 families, which was included in the previous genome-wide linkage scan with genotype data from Johns Hopkins University and Stanford University, was later re-genotyped by CIDR at the same time as the 98 new pedigrees in the primary sample in order to establish a consistent linkage map across the pedigrees. One additional family included in the previous genome-wide linkage scan was dropped from the current independent sample because the DNA from this family was exhausted. We made a common genetic map of all markers, genotyped at both stages, with the order and genetic distances based on the Marshfield map. Markers that were genotyped at both stages (n = 316) were given unique labels and placed next to each other on the map. After cleaning the data using identical procedures as described above, there was a total of 541 genotyped subjects in 64 pedigrees. Of these, 300 were diagnosed with a major mood disorder, including seven with SAM, 127 with BPI, 97 with BPII and 69 with MDDR. Under the narrow affection status model, there were 111 independent sib pairs, 182 all possible sib pairs and 266 relative pairs. Under the broad affection status model, there were 163 independent sib pairs, 316 all possible sib pairs and 469 relative pairs (see Table 1 ).
Statistical analyses
We first carried out a multipoint, non-parametric linkage analysis of the genome-wide data from the primary sample using MERLIN. 7 We used the NPL all statistic to estimate the allele sharing for all affected relative pairs. Allele frequencies for the analysis were estimated from the entire sample. We analyzed two affection status models: a narrow model that included diagnoses of SAM, BPI and BPII, and a broader model that included SAM, BPI, BPII and MDDR.
In addition to reporting nominal P-values for the NPL all scores from MERLIN, we estimated empirical genome-wide levels of significance via simulation. The 'simulate' routine of MERLIN was used to permute randomly the genotype data for the families in the sample while preserving the marker allele frequencies and the missing data structure. A total of 1000 replicates were generated, and each replicate was analyzed separately for linkage in the same way as the observed sample. The peak NPL scores from each replicate were rank ordered, and the distribution was used to determine the threshold at which a finding is observed once in every 20 genome scans.
We then reanalyzed the genome-wide data from the primary sample using LODPAL, a multipoint affected relative pair program implemented in the SAGE package (version 4.4) that is capable of incorporating clinical covariates. This approach was first introduced by Olson 8 and later modified by Goddard et al.
9
It is based on a conditional logistic parameterization of the recurrence risk ratios for offspring and monozygotic (MZ) twins, conditional on covariates. The model estimates a parameter for the 'average' linkage in the sample, as well as parameters for the change in linkage as a function of the included covariates.
Results are reported as log of odds (LOD) scores, where the LOD score equals the likelihood-ratio statistic (LRS) from the fitted model divided by 4.605 (that is, 2 Â loge10). As P-values derived on the basis of the asymptotic distribution of the LRS may be anticonservative, we evaluated the significance of our best findings using permutation methods. In order to test the covariate effect on linkage, we randomly permuted the covariate values among the affected relative pairs 1000 times while holding the genotype data fixed. We then analyzed each replicate across the entire genome with LOD-PAL. The number of times there was an improvement in LOD score, at a particular locus greater than that in the observed data set divided by 1000, was taken as the pointwise empirical P-value for the covariate effect. To determine the threshold for genome-wide significance of the covariate effect, we rank ordered the highest improvement in LOD score from each replicate, and the resulting distribution was used to determine the cutoff at which a finding is observed once in every 20 replicates. Similarly, in order to test the overall linkage at a locus with a covariate, we kept the covariate fixed but randomly permuted the genotypes across the genome 1000 times using the simulation routine in MERLIN. We then analyzed each replicate with LODPAL to determine the number of times there was a LOD score at a particular locus as high as that in the original data. This number divided by 1000 was taken as the pointwise empirical P-value for overall linkage. To determine the threshold for genome-wide significance of overall linkage, we rank ordered the highest LOD score from each replicate, and the resulting distribution was used to determine the cutoff at which a finding is observed once in every 20 genome scans.
For the LODPAL analyses, we examined both the narrow and broad affection status models and tested the effects on linkage of three covariates, AAO, psychotic symptoms and comorbid anxiety (see Table 1 ). These were selected because they have been extensively studied by our group in the past and shown to aggregate in certain BP families, [10] [11] [12] [13] [14] suggesting that they may be markers of the underlying genetic heterogeneity in BP. Detailed information about these covariates was obtained during the subject interviews. AAO was defined as the earliest age at which the first episode of depression or mania met diagnostic criteria. It was included as a dichotomous covariate with a cutoff at age 21 years (p21 vs > 21) based on previous evidence that this empirically distinguished early-and later-onset forms of the disease.
14 Psychosis was operationalized as a dichotomous variable defined by the presence or absence of delusions and/or hallucinations. 10, 11 Anxiety was also captured as a dichotomous variable defined by the presence or absence of any one of the following comorbid anxiety disorders: panic disorder, obsessive-compulsive disorder, simple phobia or social phobia. We initially tested panic disorder by itself, as our previous research has mostly focused on this condition. 12, 13 However, analyses of the current data showed more promising results with the broader category of any anxiety disorder, perhaps because of the larger numbers of subjects with such conditions, so we only present the results of these analyses here.
We further examined our top findings in the covariate analyses by testing them in the independent sample. We chose a relatively stringent threshold of LOD scores greater than 3.0 for follow-up in order to increase the chances of detecting true positive findings, while minimizing the number of spurious tests carried out. For each of the selected findings, we retested the same covariate under both the broad and narrow affection status models across the entire chromosome. We used the same procedures, as described above, to calculate empirical P-values for the results.
Results
We conducted a genome-wide linkage scan of 98 newly ascertained BP pedigrees with a panel of 402 markers genotyped at CIDR. The average information content across the markers was 0.68. The NPL plots across each chromosome for both affection status models are shown in Figure 1 , and the top findings with a nominal Pp0.05 are reported in Table 2 . Three loci were nominally significant under the narrow model. The best finding was on chromosome 2q24 at marker D2S1776 with an NPL of 2.54 (P = 0.005) and allele sharing LOD score of 1.99 (P = 0.001). The region of significantly elevated allele sharing (defined by a nominal P < 0.05) extended for more than 20 cM between markers D2S1353 and D2S1391. Eight loci were nominally significant under the broad model. The best finding was on chromosome 3q28 at marker D3S2418 with an NPL of 2.4 (P = 0.008) and an allele sharing LOD score of 1.94 (P = 0.001). The region of significantly elevated allele sharing (defined as above) extended for more than 15 cM from beyond marker D3S2398 to the final telomeric marker D3S1311. None of the findings exceeded the threshold for genome-wide levels of significance, which we calculated via simulations in this data to be an NPL of 3.22 under the narrow model and 3.18 under the broad model.
We reanalyzed the genome-wide data using LODPAL in order to incorporate salient information about clinical covariates. We separately examined three different covariates that previous research has suggested may be relevant to the genetic heterogeneity of BP, including AAO, psychosis and anxiety. The LOD plots across each chromosome, with and without the inclusion of the covariates under the narrow and broad models, are shown in Figures 2-4 , and the best findings with an overall LOD > 3.0 are reported in Table 3 . The results of further analyses of these top findings in the independent sample are also shown in Table 3 .
None of the findings using these clinical covariates exceeded the thresholds for genome-wide levels of One locus achieved an LOD > 3.0 with dichotomized AAO. Interestingly, this was on chromosome 3q28 at marker D3S2418 in the narrow model, the same marker that yielded a peak finding in the genome-wide scan in the broad model. In the LODPAL analysis, this locus was associated with a baseline LOD of only 0.06, which increased to 3.49 with the inclusion of AAO as a covariate. The empirical P-value was 0.007 for the overall LOD and 0.002 for the covariate effect. In the independent sample, the LOD increased from 0.00 to 1.00 at a neighboring marker D3S1311 approximately 10 cM away. The empirical P-value here was 0.072 for the overall LOD and 0.024 for the covariate effect. In both the primary and independent samples, the parameter for the AAO covariate was negative, suggesting that the evidence of linkage was consistently greatest among early-onset subjects.
Three loci achieved an LOD > 3.0 with psychosis. These were on chromosomes 12p13, 12q15 and 11p11. Of these, only the locus on 11p11 also showed a significant covariate effect in the independent sample. In the primary sample, the LOD increased at marker D11S1344 from 0.00 to 3.96. The empirical P-value was 0.001 for the overall LOD and < 0.001 for the covariate effect (that is, there were no replicates out of 1000 that showed a similar increase in LOD with the permuted covariate values). In the independent sample, the LOD score increased from 0.004 to 1.96 at a neighboring marker D11S1993 that was < 5 cM away. Here, the empirical P-value was 0.01 for the overall LOD and 0.008 for the covariate effect. The parameter estimate for the psychosis covariate was negative in the primary sample, but positive in the independent sample.
Only one locus achieved an LOD > 3.0 with the anxiety covariate. This was on chromosome 17q25.3. At marker D17S784, the LOD increased from a baseline of 0.81 to 3.11, which was associated with an empirical P-value of 0.001 for the overall LOD and 0.008 for the covariate effect. In the independent sample, the LOD increased at this marker from 0.27 to 1.51, for an empirical P-value of 0.034 for the overall LOD and 0.028 for the covariate effect. Interestingly, the peak in the independent sample was even greater at marker D17S2153, which is approximately 30 cM centromeric to D17S784. Here, the LOD increased from 0.40 to 3.19, yielding an empirical P-value of 0.004 for the overall LOD and 0.004 for the covariate effect. Again, the estimated parameters for the anxiety covariate had opposite signs in the primary and independent samples.
Discussion
We carried out a genome-wide linkage scan of BP with 98 newly ascertained multiplex families. The best findings were on chromosomes 2q24 and 3q28, but neither of these achieved genome-wide significance. In total, three loci were nominally significant under a narrow diagnostic model and seven other loci were nominally significant under a broader model. Many of these loci have been reported in previous linkage studies of mood disorders. These patterns of nominal findings, which do not exceed rigorous thresholds of significance but are implicated by previous scans, appear to be typical of linkage studies of complex psychiatric disorder and may be due to the presence of extensive genetic heterogeneity. In order to address such heterogeneity, we carried out a systematic linkage analysis with clinical covariates, which prior Abbrevaitions: AAO, age at onset; LOD, log of odds. a A positive delta parameter indicates the LOD score increase occurs in the presence of the trait, while a negative value indicates the LOD scores increase occurs in the absence of the trait. b These are point-wise empirical P-values.
evidence suggests may reflect the underlying heterogeneity. Again, no genome-wide significant loci were found in these analyses, although there were results in our primary sample, for which the same loci were identified in an independent sample on chromosomes 3q28 with AAO, 11p11 with psychosis and 17q25 with comorbid anxiety. The three nominally significant loci identified in the genome scan without covariates under the narrow model were on chromosomes 2q24, 1q44 and 15q22. Of these, chromosomes 2q24 and 1q44 have been implicated in previous studies of BP. A study by Cichon et al. 15 showed suggestive evidence of linkage across a broad region on chromosome 2q21-33 and this region was also implicated in Middleton et al. 16 On chromosome 1q44, Cheng et al. 17 reported a finding at D1S1609, the same marker where our peak occurred. Interestingly, DISC1, which has been the focus of extensive research in both schizophrenia and BP disorder, 18 is approximately 11 Mb away.
The seven other nominally significant loci under the broad model were on chromosomes 3q28, 12p11, 12q23, 7q22, 19q13, 10q26 and 9p24. Of these, chromosomes 3q28, 12q23 and 10q26 have been implicated by previous studies. Badenhop et al. 19 found their strongest evidence for linkage across a large region that spanned 3q25-26. Kelsoe et al. 20 reported suggestive evidence of linkage at D3S2398, which is just over 3 Mb away from our finding. Similarly, Bailer et al. 21 examined a mixed sample of schizophrenia and BP families and reported a top finding at D3S1265, < 5 Mb away.
Chromosome 12q23 has received a great deal of attention in BP since reports by Craddock et al. 22, 23 of co-segregation in two large families of major affective disorders and Darier's Disease, which has been localized to the gene ATP2A2 in this region. A number of other studies have since reported linkage of BP and recurrent major depression to this region. [24] [25] [26] [27] [28] [29] [30] However, no susceptibility gene for these disorders has yet been identified in this region.
On 10q26, Kelsoe et al. 20 reported a finding at D10S1223, approximately 5 Mb from our current peak. We found suggestive evidence of linkage to this same marker in a previous examination of the 65 pedigrees that comprise the independent sample in the current study, and this marker was also the second strongest finding in the study of Cichon et al. 15 Finally, the region was implicated by Ewald et al. 31 In the analysis with covariates, we first examined AAO. Previous studies 14, 32, 33 have shown that AAO may distinguish between several sub-populations of BP that have distinct clinical presentations and cluster within families. Our best finding, which replicated in two independent samples, was on chromosome 3q28. This locus was also the best finding in the genome-wide linkage analysis without covariates under the broad diagnostic model. The covariate analysis suggested that the linkage was strongest among those with an earlier onset.
We previously examined AAO in a similar covariate linkage analysis of families from the NIMH Genetics Initiative BP Collaborative and reported findings on chromosomes 18p and 21q. In the current analysis, these loci did not meet our thresholds for follow-up in the independent sample. However, consistent with our previous findings, we did note some evidence of increased linkage on 18p, where the LOD increased from 0.0 to 1.03 with the inclusion of AAO (see Figure 2) . Faraone et al. 34, 35 also examined the effect of AAO on linkage in a subset of families from the NIMH Genetics Initiative BP Collaborative. They reported findings from one analysis on chromosomes 12p, 14q and 15q and from another analysis on chromosome 9q34. The divergent findings may be attributed to differences in the methods used to incorporate AAO as a covariate in the linkage analysis and in the definition of AAO.
Another promising clinical feature that may serve as a useful marker of the underlying heterogeneity of BP is psychosis. About 58% of manias include delusions and/or hallucinations, 36 and these features tend to aggregate in certain BP families. 10, 11, 37 Such observations have motivated several studies to examine linkage in BP with psychosis. Our group previously carried out a stratified linkage analysis of BP families loaded with relatives having psychotic symptoms and found significantly increased evidence of linkage in two regions on chromosomes 13q31 and 22q12. 38 Another group reported genome-wide significant linkage to BP with psychosis on chromosomes 9q31 and 8p21. 39 That same group studied a separate sample and found genome-wide significant linkage to BP with psychosis on chromosome 16p12. 17 Several of these loci fall within regions that have been implicated in previous studies of BP and schizophrenia. 40 This has led some investigators to propose that psychotic features in BP may reflect an overlap in the etiology of the two disorders.
In the current analysis of psychosis, only one locus reached our threshold for follow-up and was also identified in the second sample of families. This was on chromosome 11p11. While this locus has not been previously reported in linkage analyses of BP with psychosis, it has been implicated in a scan of BP 16 and in another of schizophrenia. 41 Additionally, this region is < 18 Mb away from BDNF, which has been associated with both BP and schizophrenia. 42 Given the low resolution of the linkage method, it is hard to determine whether the current finding represents the same locus or not.
Finally, we examined comorbid anxiety as another covariate in the linkage analysis. We initially focused on panic disorder based on our previous findings that comorbidity with it aggregates in BP families. 12, 13 However, none of the findings from this analysis reached our threshold for follow-up, so we broadened our investigation to include all comorbid anxiety disorders. When we did this, we noted a finding on chromosome 17q25 that replicated across our two samples. Modest evidence of linkage to 17q25 was seen in a previous genome scan of the first two waves of families from the NIMH Genetics Initiative BP Collaborative. A genome scan of the third wave yielded even stronger evidence for linkage to 17q25. 43 Additionally, Ewald et al. 44 identified evidence of linkage nearby. However, no other study has explicitly examined linkage to BP and comorbid anxiety. Interestingly, chromosome 17q25 has been implicated in linkage scans of hoarding behavior, 45 a common symptom of obsessive compulsive disorder, and anxiety related traits in anorexia. 46 For both the findings on 11p11 and 17q25, the increased evidence of sharing with the covariate went in opposite directions in the primary and independent samples. On 11p11 the evidence of linkage was increased among subjects without psychosis in the primary sample, while it appeared to be increased among subjects with psychosis in the independent sample. Conversely, on 17q25 the evidence of linkage was increased among those with comorbid anxiety in the primary sample, while it was increased among those without comorbid anxiety in the independent sample. It is unclear how to reconcile these apparently discrepant findings. One possibility is that the implicated loci contain both susceptibility and protective alleles, for which the two samples are differentially enriched. However, further methodological work is clearly needed to better understand how analyses that utilize covariates are influenced by the underlying genetic architecture of disease susceptibility.
There are at least three additional limitations to the current study. First, the power to detect linkage with the available sample may have been limited. Under the broad affection status model, we estimated that we had 80% power to detect, at genome-wide significance, a locus with l s = 3.00. The l s may be much smaller for complex disorders like BP. Second, the information content of our microsatellite marker scan (average content = 0.68) is modest compared to what is now available using single nucleotide polymorphism (SNP) linkage marker sets. As a result, our power to detect true linkage signals may have been further limited. Our sample will be re-genotyped using a denser SNP map in the near future. Third, there may be single clinical features, or constellations of them, that increase genetic homogeneity more powerfully than those we employed. Use of a systematic approach to data reduction, such as latent class or factor analysis, and application of covariates derived from these methods in linkage may be the most appropriate means of addressing this issue.
It seems increasingly likely that the genetic etiology of BP is very heterogeneous with many susceptibility genes of small effects. This has made it very challenging to identify the genetic factors that contribute to disease. Although none of the findings in the current scan reach genome-wide levels of significance, the fact that many of the loci identified have been implicated in previous studies of BP increases the likelihood that they are true positives and merit further investigation. We believe it will be important to continue to utilize the detailed clinical information on BP in order to facilitate the follow-up of these findings.
